RxDoctor Payments Data

Katherine Peil

Adult Medicine · Sumter, SCNPI 1467061481

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 30.3% of the total. 2025 is the largest year on record at $2,540, 6.6 times the $387 reported in 2021.

$8,043in general payments, 2019–2025

Across 435 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$725
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$719
  • Lilly USA, LLC$474
  • Takeda Pharmaceuticals U.S.A., Inc.$413
  • Phathom Pharmaceuticals, Inc.$346
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$7,97899%
  • Education$521%
  • Gifts$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult medicine providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,839
Medicare patients
291
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac56$9,499
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates58$3,633
Colestipol Hcl23$2,258
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag16$1,967
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl98$1,690
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl59$988
Omeprazole12$262
Famotidine19$239
Pantoprazole Sodium14$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$37$9,49956 claims
Braintree Laboratories, Inc.Suflave$105$1,96716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other adult medicine in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →